ArticleAmerican journal of translational research2026
Sodium-glucose cotransporter 2 inhibitors reduce new-onset heart failure and death after myocardial infarction with a preserved ejection fraction following coronary intervention.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate whether SGLT2is (sodium-glucose cotransporter-2 inhibitors prevent new-onset heart failure (HF) in patients with preserved left ventricular ejection fraction (LVEF) following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
methodsThis retrospective cohort study enrolled AMI-PCI patients with LVEF ≥ 50% and no prior HF. Based on discharge medication, patients were assigned to a SGLT2i group (empagliflozin or dapagliflozin 10 mg once daily) or a non-SGLT2i group. After 1:1 propensity score matching (PSM), 115 matched pairs were identified. Fasting glucose, lipid profiles, estimated glomerular filtration rate (eGFR), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin I (hs-cTnI), and echocardiographic values were assessed within 72 hours post-PCI. The primary outcome was the occurrence of new-onset HF events; secondary outcomes included all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACE). Follow-up period was at least 18 months.
resultsSGLT2i significantly reduced new-onset HF events (6.09% vs. 15.65%, P=0.020), all-cause mortality (3.48% vs. 10.43%, P=0.038), cardiovascular mortality (1.74% vs. 9.57%, P=0.010), and MACE (7.83% vs. 18.26%, P=0.019). Multivariable Cox regression confirmed SGLT2i use as an independent protective factor (HR, 0.583; 95% CI, 0.371-0.916; P=0.017).
conclusionAmong patients with AMI undergoing PCI and preserved LVEF, SGLT2 inhibitor use was associated with a significant reduction in new-onset HF events and improved survival outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.